{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:34:07Z","timestamp":1795084447453,"version":"4.10.2"},"reference-count":18,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T00:00:00Z","timestamp":1187827200000},"content-version":"vor","delay-in-days":4831,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Psychiatr Scand"],"published-print":{"date-parts":[[1994,6]]},"abstract":"<jats:p>The efficacy of moclobemide (300\u2013450 mg7sol;day) was compared with fluoxetine (20\u201340 mg\/day) in a double\u2010blind, multicentre study in 209 patients with new episodes of depression selected from 612 consecutive depressed patients representative of those consulting psychiatric services in Finland. Antidepressant efficacy was assessed with the Hamilton Depression Rating Scale (HDRS), Montgomery\u2010\u00c5sberg Depression Rating Scale and Clinical Global Impression (CGI). The Medical Outcome Study Short\u2010form General Health Survey (SF\u201020) and 15D Measure of Quality of Life were used to measure effectiveness in terms of health\u2010related quality of life. Efficacy was evident with both drug treatments, with 67% in the moclobemide group and 57% in the fluoxetine group having a reduction in HDRS of more than 50%. Similarly, 77% of the patients in the moclobemide group and 67% in the fluoxetine group were assessed on the CGI as much better or very much better after 6 weeks of treatment. The most commonly reported adverse events were nausea, other gastrointestinal symptoms, nervousness, dizziness and sleep disorders. Nausea was significantly more common in the fluoxetine group and was found especially in women. Premature terminations of treatment were 18% in the moclobemide and 21% in the fluoxetine group. A significant change for the better in quality of life was found in both treatment groups, even at week 2 but especially after 6 weeks of treatment. Improvement was not only seen in dimensions measuring depression or mental health but also in other dimensions.<\/jats:p>","DOI":"10.1111\/j.1600-0447.1994.tb01530.x","type":"journal-article","created":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T12:55:03Z","timestamp":1187873703000},"page":"363-369","source":"Crossref","is-referenced-by-count":56,"title":["Antidepressant efficacy and quality of life in depression: a double\u2010blind study with moclobemide and fluoxetine"],"prefix":"10.1111","volume":"89","author":[{"given":"J.","family":"Lonnqvist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Sintonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Syv\u00e4lahti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Appelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Koskinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Mannikko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.\u2010P.","family":"Mehtonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Naarala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sihvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Auvinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Pitkanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,8,23]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1990.tb05317.x"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199300730-00002"},{"issue":"6","key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1192\/S0007125000297535","article-title":"Efficacy and tolerability of moclobemide compared with imipramine in the depressive disorder (DSM\u2010III). An Austrian, doubleblind, multi\u2010centre study","volume":"155","author":"Baumhackl U","year":"1989","journal-title":"Br J Psychiatry"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1192\/S0007125000297523"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.160.4.519"},{"issue":"1","key":"e_1_2_1_7_2","first-page":"12","article-title":"A double\u2010blind placebo controlled comparison of moclobemide and amitriptyline in the treatment of depression","volume":"37","author":"Bakish D","year":"1992","journal-title":"Can J Psychiatry"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.306.6879.683"},{"key":"e_1_2_1_9_2","first-page":"524","article-title":"Etude multicentrique comparant l'efficacit\u00e9 et al. tol\u00e9rance du moclob\u00e9mide et de la fluvoxamine chez des patients hospitalis\u00e9s et ambulatoires pr\u00e9sentant un \u00e9pisode d\u00e9pressif majeur","volume":"80","author":"Barrelet L","year":"1991","journal-title":"Schweiz Rundsch Med Prax"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246249"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199300730-00006"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1989.03430070062031"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(92)90004-U"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-198807000-00007"},{"key":"e_1_2_1_15_2","first-page":"85","article-title":"A generic 15 dimensional measure of health\u2010related quality of life (15D)","volume":"26","author":"Sintonen H","year":"1989","journal-title":"J Soc Med"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-011-2988-6_9"},{"issue":"3","key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1192\/S0007125000297304","article-title":"Fluoxetine: efficacy against placebo and by dose \u2010 an overview","volume":"153","author":"Hall J","year":"1988","journal-title":"Br J Psychiatry"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-76580-3_16"},{"key":"e_1_2_1_19_2","article-title":"Ilmastonvaikutus TULE\u2010oireisten astmaatikkojen kuntoutuksessa","volume":"9","author":"Karhu I","year":"1993","journal-title":"Miina Sillanp\u00e4\u00e4n s\u00e4\u00e4t\u00f6n julkaisuja B"}],"container-title":["Acta Psychiatrica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0447.1994.tb01530.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0447.1994.tb01530.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T08:10:31Z","timestamp":1695888631000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0447.1994.tb01530.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,6]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1994,6]]}},"alternative-id":["10.1111\/j.1600-0447.1994.tb01530.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0447.1994.tb01530.x","archive":["Portico"],"relation":{},"ISSN":["0001-690X","1600-0447"],"issn-type":[{"value":"0001-690X","type":"print"},{"value":"1600-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,6]]}}}